Vanguard Group Inc. raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,264,579 shares of the company’s stock after acquiring an additional 354,024 shares during the period. Vanguard Group Inc. owned approximately 10.62% of IDEXX Laboratories worth $1,495,488,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in IDXX. BlackRock Inc. increased its holdings in IDEXX Laboratories by 1,967.1% in the 1st quarter. BlackRock Inc. now owns 6,427,027 shares of the company’s stock valued at $993,680,000 after acquiring an additional 6,116,102 shares during the last quarter. State Street Corp increased its holdings in IDEXX Laboratories by 38.6% in the 1st quarter. State Street Corp now owns 3,911,739 shares of the company’s stock valued at $604,793,000 after acquiring an additional 1,089,880 shares during the last quarter. Old Mutual Global Investors UK Ltd. bought a new stake in IDEXX Laboratories in the 2nd quarter valued at $83,723,000. Renaissance Technologies LLC increased its holdings in IDEXX Laboratories by 59.1% in the 1st quarter. Renaissance Technologies LLC now owns 975,600 shares of the company’s stock valued at $150,838,000 after acquiring an additional 362,400 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in IDEXX Laboratories by 64.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 887,703 shares of the company’s stock valued at $137,248,000 after acquiring an additional 349,344 shares during the last quarter. Institutional investors own 87.64% of the company’s stock.
In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 58,000 shares of the stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $155.00, for a total transaction of $8,990,000.00. Following the completion of the transaction, the chairman now owns 1,043,034 shares of the company’s stock, valued at $161,670,270. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lawrence D. Kingsley bought 2,000 shares of the stock in a transaction on Thursday, August 3rd. The shares were bought at an average cost of $151.76 per share, with a total value of $303,520.00. Following the purchase, the director now owns 3,344 shares of the company’s stock, valued at $507,485.44. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 151,734 shares of company stock valued at $23,436,626. 2.77% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Vanguard Group Inc. Increases Holdings in IDEXX Laboratories, Inc. (IDXX)” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/09/24/vanguard-group-inc-increases-holdings-in-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at 157.50 on Friday. The stock has a market capitalization of $13.75 billion, a PE ratio of 54.18 and a beta of 0.49. IDEXX Laboratories, Inc. has a 1-year low of $102.45 and a 1-year high of $173.01. The company’s 50 day moving average is $154.86 and its 200-day moving average is $159.27.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The firm had revenue of $508.90 million during the quarter, compared to analysts’ expectations of $502.44 million. During the same period last year, the business earned $0.74 earnings per share. IDEXX Laboratories’s revenue was up 9.1% compared to the same quarter last year. Analysts forecast that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current fiscal year.
A number of brokerages have issued reports on IDXX. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $182.00 price target on the stock in a report on Wednesday, June 28th. Aegis began coverage on shares of IDEXX Laboratories in a report on Wednesday, May 31st. They issued a “sell” rating and a $118.00 price target on the stock. They noted that the move was a valuation call. Bank of America Corporation upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a report on Wednesday, August 23rd. BidaskClub downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 5th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. IDEXX Laboratories presently has a consensus rating of “Hold” and a consensus price target of $174.00.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.